PRESS

PRESS RELEASES

June 22, 2022

Gemelli Biotech Completes $19 Million Series A Financing

Gemelli Biotech Corp. (“Gemelli”), a company focused on improving health by providing precision diagnostics for gastrointestinal (GI) diseases, today announced the completion of a $19 million Series A financing. Blue Ox Healthcare Partners (“Blue Ox”), a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, CerraCap Ventures, and several family offices.

Read More

October 27, 2020

Gemelli Biotech Launches Novel Breath Test Measuring Hydrogen, Methane and Hydrogen Sulfide

Los Angeles- and Raleigh-based Gemelli Biotech announced the launch of a novel breath test called trio-smart™ that provides a more complete fermented gas profile of a patient’s microbiome by measuring levels of hydrogen, methane, and hydrogen sulfide after the consumption of a sugar substance (lactulose or glucose). trio-smart™ is a Laboratory Developed Test (LDT) conducted at a CLIA-certified lab.

Read More

October 15, 2019

Gemelli Biotech, Innovator in Microbiome Space, Producer of ibs-smart™, Announces Scientific Advisory Board

Gemelli Biotech, producers of the ibs-smart™ blood test for irritable bowel syndrome with a diarrheal component (IBS-D and IBS-M), announced the formalization of a Scientific Advisory Board to support the company’s expansion into new markets and new offerings.

Read More

May 20, 2019

Second-Generation Blood Test for Irritable Bowel Syndrome (IBS) Validated as Providing Most Conclusive Diagnosis of Inclusion for IBS

Gemelli Biotech, in partnership with the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, announced new findings that validate a second-generation diagnostic blood test for irritable bowel syndrome (IBS) as the most accurate ever.

Read More

January 9, 2019

New ELISA blood test from Gemelli Biotech offers important insights to patients with Scleroderma and Systemic Sclerosis

The new blood test, sclero-smart™, measures levels of anti-vinculin, recently found to be elevated in patients with scleroderma and associated with gastrointestinal complications. This suggests a link between scleroderma and the gut microbiome, a finding that could open the door to discoveries of new microbiome-related therapeutic and diagnostic tools for scleroderma.

Read More

October 10, 2018

Launch of ibs-smart™, an advancement in blood testing for Irritable Bowel Syndrome (IBS) announced by Gemelli Biotech™ in partnership with the Medically Associated Science and Technology Program (MAST) at Cedars-Sinai

Gemelli Biotech™, a specialty biotechnology company focused on developing novel diagnostics and therapeutics for the human microbiome, announced the commercial availability of ibs-smart™, a second-generation blood test for Irritable Bowel Syndrome (IBS). ibs-smart™ offers an advancement in the specificity and accuracy of measuring two antibodies (anti-CdtB and anti-vinculin) in diagnosing Diarrhea Predominant and Mixed-Type IBS (IBS-D and IBS-M).

Read More